A novel therapeutic platform to increase tumour immunogenicity

Although cancer immunotherapy has come of age, such therapies are currently only beneficial for some patients, particularly those with tumours with lots of mutations. Therefore, new therapies desperately need to be developed. Our approach is to make tumours look like virally infected cells enabling a patient's own naturally pre-existing immune cells to recognise and destroy tumours.  There are many advantages to our innovation. As it utilises natural immunity, it will be less toxic with fewer side effects compared to other treatments. The immune responses can be highly controlled.  We can target solid tumours, which are often not treatable with current immunotherapies. Furthermore, our treatment will be cheaper than cell-based therapies.  We expect our work to widen cancer immunotherapy as a valid treatment option to a larger cohort of patients, including those with disease resistant to current immune based treatments, and to bring tangible clinical benefits to patients.